News | Deal AnnouncementSVB Securities Served as PIPE Placement Agent to Frazier Lifesciences Acquisition Corp. (Nasdaq: FLAC) and Financial Advisor and Capital Markets Advisor to NewAmsterdam Pharma in Connection with its Completed Merger and $235 Million PIPENovember 2022
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Surgery Partners’ (Nasdaq: SGRY) $575 Million Public Offering of Common StockNovember 2022
News | Deal AnnouncementSVB Securities Serves as Lead-Left Bookrunner for scPharmaceuticals (Nasdaq: SCPH) $50.0 Million Follow-On OfferingNovember 2022
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Natera’s (Nasdaq: NTRA) $400 Million Follow-On OfferingNovember 2022
News | Deal AnnouncementSVB Securities Serves as Financial Advisor to Lantheus (NASDAQ: LNTH) on its Exclusive Licensing Agreements with Point Biopharma (NASDAQ: PNT)November 2022
News | Deal AnnouncementSVB Securities Serves as Financial Advisor to Molded Devices, Inc. (MDI), a Portfolio Company of TruArc Partners, on its Acquisition of GlobalMedNovember 2022
News | Deal AnnouncementSVB Securities Serves as Lead-Left Bookrunner for Marinus Pharmaceuticals’ (Nasdaq: MRNS) $60 Million Follow-On OfferingNovember 2022
News | Deal AnnouncementSVB Securities Serves as Financial Advisor to Lumanity on its Acquisition of Clarion HealthcareNovember 2022